Champions Oncology, Inc. (CSBR) Q1 2023 Earnings Call Transcript

Sep. 09, 2022 4:41 PM ETChampions Oncology, Inc. (CSBR)
SA Transcripts profile picture
SA Transcripts
133.63K Followers

Champions Oncology, Inc. (NASDAQ:CSBR) Q1 2023 Earnings Conference Call September 8, 2022 4:30 PM ET

Company Participants

Ronnie Morris - CEO

David Miller - CFO

Conference Call Participants

Matt Hewitt - Craig-Hallum Capital Group

Operator

Good day, ladies and gentlemen, and welcome to the First Quarter Fiscal Year 2023 Champions Oncology Conference Call [Operator Instructions].

It is now my pleasure to turn the floor over to your host, Ronnie Morris, CEO of Champions Oncology. Sir, the floor is yours.

Ronnie Morris

Good afternoon. I'm Ronnie Morris, CEO of Champions Oncology. Joining me today is David Miller, our Chief Financial Officer. Thank you for joining us for our quarterly earnings call.

Before I begin, I will remind you that we'll make forward-looking statements during today's call and that actual results could differ materially from those described in those statements. Additional information on factors that could cause results to differ is available on our Forms 10-Q and Form 10-K.

A reconciliation of non-GAAP financial measures that may be discussed during the call to GAAP financial measures is available in the earnings release.

I'll start by pointing out that our prepared comments for today will be relatively brief as we just recently provided our fiscal year-end results and company update six weeks ago.

On that call, I provided an update on the strategic path we embarked on in fiscal year 2022, highlighting the exciting opportunities for Champion over the next several years. Those included growing our core services while investing in other areas such as data and drug discovery. The first quarter was representative of the continuity we strive for, while executing on our strategy.

Our oncology research services business, which includes in vivo and ex vivo studies, along with an extensive array of biomarker assays continues to grow with another record high in our

Recommended For You

Comments

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.